Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

[News]

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.

More... (http://www.news-medical.net/news/20111012/Merrimack-begins-MM-121-Phase-2-combination-trial-in-HER2-negative-breast-cancer.aspx)